StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note issued to investors on Tuesday. The firm issued a sell rating on the stock.
Navidea Biopharmaceuticals Stock Performance
NYSE NAVB opened at $0.04 on Tuesday. Navidea Biopharmaceuticals has a 12 month low of $0.02 and a 12 month high of $0.19. The stock has a market cap of $3.50 million, a PE ratio of -0.58 and a beta of 1.13. The stock’s 50 day moving average is $0.04 and its 200 day moving average is $0.05.
Navidea Biopharmaceuticals Company Profile
See Also
- Five stocks we like better than Navidea Biopharmaceuticals
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Garmin Navigates to New Highs Driven By Wearables Trend
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- The 3 Best Retail Stocks to Shop for in August
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.